Ann: Proactive Investors Interview with Orthocells MD, page-28

Avetis, with respect, you are talking about large scale Phase III drug trials with massive Monte Carlo, meta analysis and the like on compatibility with other drugs, safety, etc. This is a small Phase II trial by little ole' OCC ultimately - if sponsored by J&J. A pivotal one, but not huge amount of data for empirical testing. A lot of qualitative interpretation with MRI analysis, pain scores and functional measures (OSS, CMS and ASES - composite outcome) rather than quantitative analysis. As Roughie is suggesting, JNJ may even have the data already. Sounds like Roughie thinks they have a months exclusivity on the data written into the original contract and then we get it - he is more informed than I on that. Early to mid-October IF they've given JNJ the data already and that is the case.

@roughie12 I always said I never wanted a JNJ takeover, knowing the share price would go so much further if the company rolled it all out in partnership with them. Right now I am that weary of this stock price performance I'd happily take a $1.50 script takeover and stay in JNJ (which I already own) on the back of CelGro and ATI in part. I am on Astra-Zenica which has made very good money on cellular treatments whilst everyone focuses on its vaccine (which was not for profit - I'd just drop it, if I was them).

OCC at $1.50 for JNJ $USD 215 million worth of shares. I mean they only announced $6,600 million in profits in a quarter. Do you think J&J might spare $215 million from their forecast $24,000 million 2022 net income to add possibly a possible future $5 billion to their $100 billion top line?

Have a good weekend all, after another crappy two month share price move in OCC. Hopefully we will get a takeover or partnership and we can all be allowed to go to the pub in late October to celebrate.